content_image/217416.jpg content_image/217415.jpg
## Immunology ( including Transplantation ) and Infectious Diseases 

W orldwide sales of Prograf have held up due to growth in Japan, Asia & Oceania. 

In the field of immunology including transplantation, Astellas is working to sustain its Prograf business on a global scale. 

Sales of Prograf (including the once-daily formulation Advagraf/Graceptor/ASTAGRAF XL) rose 12% year on year in fiscal 2013 to ¥181.4 billion, partly due to the effect of foreign exchange rates. Local-currency sales declined in the Americas and EMEA due to generic  competition, but global sales held up as the result of growth in Japan and Asia & Oceania. 

Sales in Japan rose 2.0% due to steady growth in Graceptor. The growth was partially offset by a fall in sales after the entry of generic versions of the drug in June 2013. Generic competition also eroded sales in the  Americas, where sales declined 22% year on year on a U.S. dollar basis. We launched ASTAGRAF XL in the U.S. in August 2013. In EMEA, while sales of Advagraf contin- ued to grow, price reductions in multiple countries and generic competition led to a 1.3% decline in euro-based sales of Prograf via in-house distribution channels. 

<img src='content_image/217416.jpg'>

Supported by growth in China and South Korea, sales increased 32% in Asia & Oceania. 

Rheumatoid arthritis treatment Cimzia, which was launched in Japan in March 2013, posted fiscal 2013 sales of ¥3.2 billion. In June 2014, we filed an application for the approval of an expanded indication that includes rheumatoid arthritis in patients not previously treated with anti-rheumatic drugs. In the field of infectious diseases, sales in fiscal 2013 of Funguard/MYCAMINE rose 18% compared with the previous year, partly due to foreign exchange effects. 

In terms of the pipeline for new drug candidates to follow these products, in the field of infectious diseases, Astellas filed new drug applications in Japan for ASP7374 (seasonal influenza vaccine) in May 2014 and in the U.S. for isavuconazole (azole antifungal) in July 2014. In the field of immunology including transplantation, Astellas is conducting clinical trials on ASP015K (for the treatment of rheumatoid arthritis) and ASKP1240 (for the prevention of organ transplant rejection). 

<img src='content_image/217415.jpg'>

